|
1
|
Parkin DM, Bray FI and Devesa SS: Cancer
burden in the year 2000. The global picture. Eur J Cancer. 37(Suppl
8): S4–S66. 2001.PubMed/NCBI
|
|
2
|
Balsara BR, Sonoda G, du Manoir S,
Siegfried JM, Gabrielson E and Testa JR: Comparative genomic
hybridization analysis detects frequent, often high-level,
overrepresentation of DNA sequences at 3q, 5p, 7p, and 8q in human
non-small cell lung carcinomas. Cancer Res. 57:2116–2120. 1997.
|
|
3
|
Iwakawa R, Kohno T, Kato M, Shiraishi K,
Tsuta K, Noguchi M, Ogawa S and Yokota J: MYC amplification as a
prognostic marker of early-stage lung adenocarcinoma identified by
whole genome copy number analysis. Clin Cancer Res. 15:1481–1489.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Greulich H: The genomics of lung
adenocarcinoma: opportunities for targeted therapies. Genes Cancer.
1:1200–1210. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao X, Weir BA, LaFramboise T, Lin M,
Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG,
et al: Homozygous deletions and chromosome amplifications in human
lung carcinomas revealed by single nucleotide polymorphism array
analysis. Cancer Res. 1:5561–5570. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tonon G, Wong KK, Maulik G, Brennan C,
Feng B, Zhang Y, Khatry DB, Protopopov A, You MJ, Aguirre AJ, et
al: High-resolution genomic profiles of human lung cancer. Proc
Natl Acad Sci USA. 102:9625–9630. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li X, Wan L, Shen H, Geng J, Nie J, Wang
G, Jia N, Dai M and Bai X: Thyroid transcription factor-1
amplification and expressions in lung adenocarcinoma tissues and
pleural effusions predict patient survival and prognosis. J Thorac
Oncol. 7:76–84. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hwang KT, Han W, Cho J, Lee JW, Ko E, Kim
EK, Jung SY, Jeong EM, Bae JY, Kang JJ, et al: Genomic copy number
alterations as predictive markers of systemic recurrence in breast
cancer. Int J Cancer. 15:1807–1815. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Choe J, Kang JK, Bae CJ, Lee DS, Hwang D,
Kim KC, Park WY, Lee JH and Seo JS: Identification of origin of
unknown derivative chromosomes by array-based comparative genomic
hybridization using pre- and postnatal clinical samples. J Hum
Genet. 52:934–942. 2007. View Article : Google Scholar
|
|
10
|
Kim JI, Ju YS, Park H, Kim S, Lee S, Yi
JH, Mudge J, Miller NA, Hong D, Bell CJ, et al: A highly annotated
whole-genome sequence of a Korean individual. Nature. 20:1011–1015.
2009.PubMed/NCBI
|
|
11
|
Chochi Y, Kawauchi S, Nakao M, Furuya T,
Hashimoto K, Oga A, Oka M and Sasaki K: A copy number gain of the
6p arm is linked with advanced hepatocellular carcinoma: an
array-based comparative genomic hybridization study. J Pathol.
217:677–684. 2009. View Article : Google Scholar
|
|
12
|
Kang JU, Koo SH, Kwon KC, Park JW and Kim
JM: Identification of novel candidate target genes, including
EPHB3, MASP1 and SST at 3q26.2–q29 in squamous cell carcinoma of
the lung. BMC Cancer. 9:2372009.PubMed/NCBI
|
|
13
|
Kang JU and Koo SH: ORAOV1 is a probable
target within the 11q13.3 amplicon in lymph node metastases from
gastric adenocarcinoma. Int J Mol Med. 29:81–87. 2012.PubMed/NCBI
|
|
14
|
Willenbrock H and Fridlyand J: A
comparison study: applying segmentation to array CGH data for
downstream analyses. Bioinformatics. 21:4084–4091. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Job B, Bernheim A, Beau-Faller M,
Camilleri-Broët S, Girard P, Hofman P, Mazières J, Toujani S,
Lacroix L, Laffaire J, et al: Genomic aberrations in lung
adenocarcinoma in never smokers. PLoS One. 5:e151452010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thu KL, Vucic EA, Chari R, Zhang W,
Lockwood WW, English JC, Fu R, Wang P, Feng Z, MacAulay CE, et al:
Lung adenocarcinoma of never smokers and smokers harbor
differential regions of genetic alteration and exhibit different
levels of genomic instability. PLoS One. 7:e330032012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vogel P, Hansen GM, Read RW, Vance RB,
Thiel M, Liu J, Wronski TJ, Smith DD, Jeter-Jones S and Brommage R:
Amelogenesis imperfecta and other biomineralization defects in
Fam20a and Fam20c null mice. Vet Pathol. 49:998–1017. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Abe M, Hamada J, Takahashi O, Takahashi Y,
Tada M, Miyamoto M, Morikawa T, Kondo S and Moriuchi T: Disordered
expression of HOX genes in human non-small cell lung cancer. Oncol
Rep. 15:797–802. 2006.PubMed/NCBI
|
|
19
|
Marra L, Cantile M, Scognamiglio G,
Perdonà S, La Mantia E, Cerrone M, Gigantino V, Cillo C, Caraglia
M, Pignata S, et al: Deregulation of HOX B13 expression in urinary
bladder cancer progression. Curr Med Chem. 20:833–839.
2013.PubMed/NCBI
|
|
20
|
Bach C, Buhl S, Mueller D, García-Cuéllar
MP, Maethner E and Slany RK: Leukemogenic transformation by HOXA
cluster genes. Blood. 115:2910–2918. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Alharbi RA, Pettengell R, Pandha HS and
Morgan R: The role of HOX genes in normal hematopoiesis and acute
leukemia. Leukemia. 27:1000–1008. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eklund E: The role of Hox proteins in
leukemogenesis: insights into key regulatory events in
hematopoiesis. Crit Rev Oncog. 16:65–76. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Golub TR, Slonim DK, Tamayo P, Huard C,
Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri
MA, et al: Molecular classification of cancer: class discovery and
class prediction by gene expression monitoring. Science.
286:531–537. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu H, Li Y, Chen G, Wang J, Li Y, Wang Y,
Wei S, Zhu D, Qiu X, Wang W, et al: Detection and its clinical
significance of EGFR gene mutation and gene amplification in 187
patients with non-small cell lung cancer. Zhongguo Fei Ai Za Zhi.
12:1219–1228. 2009.(In Chinese).
|
|
25
|
Reinmuth N, Jauch A, Xu EC, Muley T,
Granzow M, Hoffmann H, Dienemann H, Herpel E, Schnabel PA, Herth
FJ, et al: Correlation of EGFR mutations with chromosomal
alterations and expression of EGFR, ErbB3 and VEGF in tumor samples
of lung adenocarcinoma patients. Lung Cancer. 62:193–201. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sholl LM, Yeap BY, Iafrate AJ,
Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu
J, et al: Lung adenocarcinoma with EGFR amplification has distinct
clinicopathologic and molecular features in never-smokers. Cancer
Res. 69:8341–8348. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yoshizawa A, Sumiyoshi S, Sonobe M,
Kobayashi M, Fujimoto M, Kawakami F, Tsuruyama T, Travis WD, Date H
and Haga H: Validation of the IASLC/ATS/ERS lung adenocarcinoma
classification for prognosis and association with EGFR and KRAS
gene mutations: analysis of 440 Japanese patients. J Thorac Oncol.
8:52–61. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Toutenhoofd SL, Foletti D, Wicki R, Rhyner
JA, Garcia F, Tolon R and Strehler EE: Characterization of the
human CALM2 calmodulin gene and comparison of the transcriptional
activity of CALM1, CALM2 and CALM3. Cell Calcium. 23:323–338. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stanislaus A, Bakhtiar A, Salleh D, Tiash
S, Fatemian T, Hossain S, Akaike T and Chowdhury EH: Knockdown of
PLC-gamma-2 and calmodulin 1 genes sensitizes human cervical
adenocarcinoma cells to doxorubicin and paclitaxel. Cancer Cell
Int. 12:302012. View Article : Google Scholar
|
